| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eva de Lago, Stefania Petrosino, Marta Valenti, Enrico Morera, Silvia Ortega-Gutierrez, Javier Fernandez-Ruiz, Vincenzo Di Marz. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical pharmacology. vol 70. issue 3. 2005-08-18. PMID:15963472. |
here, we have studied the effect in rats of a subchronic intraperitoneal treatment with three recently developed selective inhibitors of endocannabinoid uptake (vdm-11, ucm-707 and omdm-2) or with a selective faah inhibitor (n-arachidonoyl-serotonin, aa-5-ht), on the brain levels of anandamide and 2-arachidonoylglycerol (2-ag) measured by means of isotope dilution lc-ms 1, 5 and 12 h after the last treatment. |
2005-08-18 |
2023-08-12 |
rat |
| Mauro Maccarrone, Valeria Gasperi, Filomena Fezza, Alessandro Finazzi-Agrò, Antonello Ross. Differential regulation of fatty acid amide hydrolase promoter in human immune cells and neuronal cells by leptin and progesterone. European journal of biochemistry. vol 271. issue 23-24. 2005-07-06. PMID:15606754. |
unlike faah, the other proteins of the endocannabinoid system are not modulated by the two hormones. |
2005-07-06 |
2023-08-12 |
human |
| Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Naohiko Uchida, Akira Nomura, Kyohei Ohtani, Makiko Kishimoto, Akiko Morio, Takaki Imamura, Ayumu Sakai, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kurod. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neuroscience letters. vol 376. issue 3. 2005-05-26. PMID:15721218. |
because the pro129thr polymorphism reduces enzyme instability, it is unlikely that dysfunction of faah and enhanced endocannabinoid system induce susceptibility to either methamphetamine dependence/psychosis or schizophrenia. |
2005-05-26 |
2023-08-12 |
human |
| Darren Fegley, Silvana Gaetani, Andrea Duranti, Andrea Tontini, Marco Mor, Giorgio Tarzia, Daniele Piomell. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. The Journal of pharmacology and experimental therapeutics. vol 313. issue 1. 2005-05-19. PMID:15579492. |
genetic deletion of the faah gene in mice elevates brain anandamide levels and amplifies the effects of this endogenous cannabinoid agonist. |
2005-05-19 |
2023-08-12 |
mouse |
| Dale L Boger, Hiroshi Miyauchi, Wu Du, Christophe Hardouin, Robert A Fecik, Heng Cheng, Inkyu Hwang, Michael P Hedrick, Donmienne Leung, Orlando Acevedo, Cristiano R W Guimarães, William L Jorgensen, Benjamin F Cravat. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. Journal of medicinal chemistry. vol 48. issue 6. 2005-05-03. PMID:15771430. |
fatty acid amide hydrolase (faah) degrades neuromodulating fatty acid amides including anandamide (endogenous cannabinoid agonist) and oleamide (sleep-inducing lipid) at their sites of action and is intimately involved in their regulation. |
2005-05-03 |
2023-08-12 |
Not clear |
| Kazuhito Tsuboi, Yong-Xin Sun, Yasuo Okamoto, Nobukazu Araki, Takeharu Tonai, Natsuo Ued. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. The Journal of biological chemistry. vol 280. issue 12. 2005-04-21. PMID:15655246. |
bioactive n-acylethanolamines, including anandamide (an endocannabinoid) and n-palmitoylethanolamine (an anti-inflammatory and neuroprotective substance), are hydrolyzed to fatty acids and ethanolamine by fatty acid amide hydrolase. |
2005-04-21 |
2023-08-12 |
mouse |
| Kyle P Chiang, Alexandra L Gerber, Jack C Sipe, Benjamin F Cravat. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human molecular genetics. vol 13. issue 18. 2005-03-15. PMID:15254019. |
reduced cellular expression and activity of the p129t mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. |
2005-03-15 |
2023-08-12 |
human |
| Kyle P Chiang, Alexandra L Gerber, Jack C Sipe, Benjamin F Cravat. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human molecular genetics. vol 13. issue 18. 2005-03-15. PMID:15254019. |
fatty acid amide hydrolase (faah) inactivates the endogenous cannabinoid (endocannabinoid) anandamide and related lipid transmitters in vivo. |
2005-03-15 |
2023-08-12 |
human |
| Kyle P Chiang, Alexandra L Gerber, Jack C Sipe, Benjamin F Cravat. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Human molecular genetics. vol 13. issue 18. 2005-03-15. PMID:15254019. |
these findings indicate that the natural 385a snp in the human faah gene produces a mutant enzyme with reduced cellular stability, thus fortifying a potential link between functional abnormalities in the endocannabinoid system and drug abuse and dependence. |
2005-03-15 |
2023-08-12 |
human |
| Michiru Hirasawa, Yannick Schwab, Sirajedin Natah, Cecilia J Hillard, Ken Mackie, Keith A Sharkey, Quentin J Pittma. Dendritically released transmitters cooperate via autocrine and retrograde actions to inhibit afferent excitation in rat brain. The Journal of physiology. vol 559. issue Pt 2. 2005-02-10. PMID:15254151. |
depolarization of postsynaptic magnocellular neurones (which contain fatty acid amide hydrolase, a cannabinoid catabolic enzyme) caused a transient inhibition of epscs that could be blocked by both the am251 and manning compound, an oxytocin/vasopressin receptor antagonist. |
2005-02-10 |
2023-08-12 |
rat |
| Aron H Lichtman, Donmienne Leung, Christopher C Shelton, Alan Saghatelian, Christophe Hardouin, Dale L Boger, Benjamin F Cravat. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. The Journal of pharmacology and experimental therapeutics. vol 311. issue 2. 2005-01-25. PMID:15229230. |
fatty acid amide hydrolase (faah) is the primary catabolic regulator of several bioactive lipid amides in vivo, including the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. |
2005-01-25 |
2023-08-12 |
Not clear |
| Alan Saghatelian, Sunia A Trauger, Elizabeth J Want, Edward G Hawkins, Gary Siuzdak, Benjamin F Cravat. Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry. vol 43. issue 45. 2005-01-11. PMID:15533037. |
we use this method to discover several brain lipids regulated by the mammalian enzyme fatty acid amide hydrolase (faah) in vivo, including known signaling molecules (e.g., the endogenous cannabinoid anandamide) and a novel family of nervous system-enriched natural products, the taurine-conjugated fatty acids. |
2005-01-11 |
2023-08-12 |
Not clear |
| Benjamin F Cravatt, Aron H Lichtma. The endogenous cannabinoid system and its role in nociceptive behavior. Journal of neurobiology. vol 61. issue 1. 2004-12-13. PMID:15362158. |
the endocannabinoid system includes: (1) at least two families of lipid signaling molecules, the n-acyl ethanolamines (e.g., anandamide) and the monoacylglycerols (e.g., 2-arachidonoyl glycerol); (2) multiple enzymes involved in the biosynthesis and degradation of these lipids, including the integral membrane enzyme fatty acid amide hydrolase; and (3) two g-protein coupled receptors, cb1 and cb2, which are primarily localized to the nervous system and immune system, respectively. |
2004-12-13 |
2023-08-12 |
Not clear |
| Victoria E Mendizábal, Edda Adler-Graschinsk. Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Current vascular pharmacology. vol 1. issue 3. 2004-12-01. PMID:15320476. |
hence, the endocannabinoid system, including the cb1 and cb2 receptors, the metabolizing enzyme fatty acid amide hydrolase and the anandamide transporter, is a potential target for the development of novel therapeutic drugs in the treatment of various conditions, such as pain, feeding disorders and vascular disease among others. |
2004-12-01 |
2023-08-12 |
Not clear |
| Rachel J A Helliwell, Lawrence W Chamley, Katherine Blake-Palmer, Murray D Mitchell, Janice Wu, Christopher S Kearn, Michelle Glas. Characterization of the endocannabinoid system in early human pregnancy. The Journal of clinical endocrinology and metabolism. vol 89. issue 10. 2004-11-19. PMID:15472222. |
in recent years, it has been demonstrated that high circulating levels of the endogenous cannabinoid anandamide, resulting from low expression of its metabolizing enzyme fatty acid amide hydrolase (faah), may contribute to spontaneous miscarriage and poor outcome in women undergoing in vitro fertilization. |
2004-11-19 |
2023-08-12 |
human |
| Rachel J A Helliwell, Lawrence W Chamley, Katherine Blake-Palmer, Murray D Mitchell, Janice Wu, Christopher S Kearn, Michelle Glas. Characterization of the endocannabinoid system in early human pregnancy. The Journal of clinical endocrinology and metabolism. vol 89. issue 10. 2004-11-19. PMID:15472222. |
in this study, we examined the distribution of the cannabinoid receptors, cb1 and cb2, and the endocannabinoid-metabolizing enzyme faah in first trimester human placenta. |
2004-11-19 |
2023-08-12 |
human |
| Marco Mor, Silvia Rivara, Alessio Lodola, Pier Vincenzo Plazzi, Giorgio Tarzia, Andrea Duranti, Andrea Tontini, Giovanni Piersanti, Satish Kathuria, Daniele Piomell. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. Journal of medicinal chemistry. vol 47. issue 21. 2004-11-10. PMID:15456244. |
fatty acid amide hydrolase (faah) is a promising target for modulating endocannabinoid and fatty acid ethanolamide signaling, which may have important therapeutic potential. |
2004-11-10 |
2023-08-12 |
rat |
| Aron H Lichtman, Christopher C Shelton, Tushar Advani, Benjamin F Cravat. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. vol 109. issue 3. 2004-09-30. PMID:15157693. |
mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. |
2004-09-30 |
2023-08-12 |
mouse |
| Aron H Lichtman, Christopher C Shelton, Tushar Advani, Benjamin F Cravat. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. vol 109. issue 3. 2004-09-30. PMID:15157693. |
although the n-arachidonoyl ethanolamine (anandamide) binds to cannabinoid receptors and has been implicated in the suppression of pain, its rapid catabolism in vivo by fatty acid amide hydrolase (faah) has presented a challenge in investigating the physiological functions of this endogenous cannabinoid. |
2004-09-30 |
2023-08-12 |
mouse |
| Aron H Lichtman, Christopher C Shelton, Tushar Advani, Benjamin F Cravat. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. vol 109. issue 3. 2004-09-30. PMID:15157693. |
collectively, these findings demonstrate a cannabinoid receptor-mediated analgesic phenotype in faah (-/-) mice. |
2004-09-30 |
2023-08-12 |
mouse |